Food and Drug Administration

Dermatologic and Ophthalmic Drugs Advisory Committee

November 4, 2002

Slides

Optimizing the Approach to Acne Therapy, Dr. Wilma Bergfeld, MD, FACP, Cleveland Clinic Foundation (HTM) (PPT)

Understanding the Paradox of the More Clinically Meaningful Acne Global Severity Scale and the More Precise Acne Lesion Counts, Dr. Jonathan Wilkin, MD (HTM) (PPT)

FDA Perspective on Global Evaluation of Facial Acne, Dr. Brenda Carr, MD, FDA (HTM) (PPT)

Consensus Conference on Acne Classification, Dr. Peter Pouchi, MD (PDF)

Efficacy Evaluation in Acne Clinical Trials, Dr. Mohamed Alosh, PhD., et. al., FDA (HTM) (PPT)

Assessing the Relationship Between Success on the Investigator Global Evaluation and Acne Lesion Counts, Dr. Mohamed Alosh, PhD, FDA (HTM) (PPT)

Combination Topical Products for the Treatment of Acne Vulgaris, Dr. Markham Luke, MD, PhD, FDA (HTM) (PPT)

Clinical Studies Section of Labeling, Dr. Joseph Porres, MD, PhD, FDA (HTM) (PPT)